Loan-Licensing and Third-Party Manufacturing: The Pharma Reconciliation Guide

A Tier-1 Indian pharma brand-owner and market-authorisation holder closes its books on 30 September with 42 loan-licensing arrangements across Baddi (Himachal Pradesh), Selaqui (Uttarakhand), Sikkim, and Guwahati (Assam) — each producing 8 to 34 finished-dosage-form SKUs under the brand-owner’s own drug licence. The Sikkim manufacturing unit, running under the Section 80-IE 100 percent profit deduction for eligible North-Eastern manufacturing, dispatches active pharmaceutical ingredient and intermediates approximately 1,240 times a month across the loan-licensee network. Each dispatch is a Rule 45 challan-based movement without payment of tax under Section 143 of the CGST Act. The Baddi loan-licensees alone handle roughly 460 of those dispatches and return finished dosage form back to the brand-owner’s warehouse for onward supply to distributors and stockists — a Sikkim-to-Baddi and back movement that triggers IGST at 12 percent on the loan-licensee’s HSN 9988 job-work invoice because the two ends sit in different states. Layer on the ITC-04 periodic return, the Section 43B(h) 45-day MSME payment aging on the loan-licensee’s invoice, and the electronic credit ledger utilisation of the IGST job-work invoice ITC against the brand-owner’s own finished-product output tax, and the loan-licensee reconciliation surface across a full quarter runs into the low tens of thousands of individual movements — every one of which must age cleanly against the Section 143 1-year window for inputs and 3-year window for capital goods, or the deemed-supply demand with interest from the dispatch date under Section 50 accrues at the next audit. This is loan-licensing third-party manufacturing pharma CDMO reconciliation at operating scale.

Quick reference

The reconciliation in one paragraph

An Indian pharma brand-owner and market-authorisation holder running a loan-licensing arrangement retains full regulatory ownership of the product — the drug licence, the market authorisation, the label, the brand, and the goods themselves — but produces the finished dosage form at a third-party manufacturer’s plant. The brand-owner dispatches the active pharmaceutical ingredient, the intermediates, and the excipients (where retained on brand-owner books) to the loan-licensee’s plant against a Rule 45 challan without payment of tax under Section 143. The loan-licensee produces the finished dosage form under the brand-owner’s drug licence, invoices the brand-owner for the job-work service under HSN 9988 (not for the finished goods, which never legally leave the brand-owner’s inventory), and returns the finished dosage form to the brand-owner’s warehouse against a return challan referencing the original dispatch challan. The brand-owner ages every dispatch against the Section 143 1-year input window and 3-year capital-goods window; failure to return within the window deems the goods supplied on the dispatch date and attracts tax with Section 50 interest from that date at 18 percent per annum. The loan-licensee’s HSN 9988 job-work invoice at 12 percent IGST (where cross-state) or 12 percent CGST-plus-SGST aggregate (where intra-state) enters the brand-owner’s ITC pool and utilises against the brand-owner’s own finished-product output tax under the Section 49(5) utilisation order. The ITC-04 periodic return summarises the challan-level dispatch and return movements against the four ITC-04 dispatch categories. Section 43B(h) of the Income-tax Act — the 45-day MSME payment rule — attaches to any loan-licensee Udyam-registered as Micro or Small, requiring the brand-owner to age the job-work invoice payment against the Section 15 MSMED window at every balance-sheet date. Where the brand-owner’s Sikkim unit is claiming Section 80-IE, the deduction-eligible profit is worked out on the brand-owner’s own manufacture of active pharmaceutical ingredient and intermediates, cleanly segregated from the third-party’s finished-dosage-form conversion margin.

What the scenario looks like in India — the loan-licensing operating model

The loan-licensing model is the operating template that a majority of India’s Tier-1 and Tier-2 listed formulators use to expand finished-dosage-form capacity without building or acquiring incremental brick-and-mortar plants. The scaffolding is a two-part regulatory arrangement. The brand-owner — the licensing party — holds the drug licence issued by the State Drugs Controller for the specific formulation, and holds the market authorisation to sell that formulation under its own brand name. The third-party manufacturer — the loan-licensee — holds a manufacturing licence issued by the local State Drugs Controller for the physical premises and equipment where the finished dosage form is produced, but does not hold the market authorisation for the specific formulation. The two parties enter into a loan-licensing agreement that permits the loan-licensee to manufacture the specific formulation on behalf of the brand-owner, under the brand-owner’s drug licence and specifications; the manufacturing licence held by the loan-licensee is deemed extended to cover the brand-owner’s formulation for the term of the agreement, and the local State Drugs Controller endorses the loan-licence on the loan-licensee’s own manufacturing licence.

Illustrative brands operating substantial loan-licensing and third-party manufacturing networks include Alkem Laboratories (with a Sikkim manufacturing footprint under the Section 80-IE regime and a Baddi finished-dosage-form conversion presence), Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, Lupin, Aurobindo Pharma, Zydus Lifesciences, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Ipca Laboratories, Ajanta Pharma, Cadila Pharmaceuticals, and JB Chemicals & Pharmaceuticals. Baddi in Himachal Pradesh is the single largest concentration of loan-licensee capacity in the country — a legacy of the area-based excise exemption that ran from 2003 to the 2017 GST transition and left an installed base of several hundred formulation plants clustered around a single industrial corridor. Sikkim carries a parallel legacy — the Section 80-IE income-tax holiday for eligible manufacturing units in the North-Eastern states runs to 100 percent of profits for 10 consecutive assessment years — and a substantial subset of Tier-1 brand-owners run their own manufacturing unit in Sikkim for active pharmaceutical ingredient and intermediate production while dispatching to loan-licensees in Baddi, Selaqui (Uttarakhand — the parallel area-based excise beneficiary), or elsewhere for finished-dosage-form conversion. Where the brand-owner’s own Sikkim unit is the source of the active pharmaceutical ingredient and the Baddi loan-licensee is the conversion sink, the movement is inter-state under Section 7 of the IGST Act and the loan-licensee’s job-work invoice attracts IGST rather than CGST-plus-SGST — a nuance that carries through to the electronic credit ledger reconciliation on the brand-owner’s own GSTIN.

The reconciliation surface for the loan-licensing model is materially distinct from the reconciliation surface for a pure contract-manufacturing arrangement. Under contract manufacturing, the contract manufacturer holds its own drug licence and its own manufacturing authorisation for the specific formulation, procures inputs on its own books, produces the finished goods on its own account, and sells the finished goods to the buyer under a normal Section 15 supply valuation. There is no Section 143 job-work invocation, no Rule 45 challan cover, and no ITC-04 return exposure. The loan-licensing model, by contrast, is a direct invocation of Section 143 and inherits every reconciliation surface that attaches — the challan-based dispatch and return, the 1-year and 3-year window aging, the ITC-04 periodic filing, and the HSN 9988 job-work invoice tax event. When the two parties operate across state boundaries, the additional IGST-versus-CGST-plus-SGST reconciliation layer sits on top of the base Section 143 apparatus.

The regulatory overlay — Section 143 CGST, Rule 45, ITC-04, HSN 9988, and Section 43B(h)

Five regulatory anchors govern the loan-licensee reconciliation surface, each mapping to a specific control point in the brand-owner’s finance workflow.

Section 143 of the CGST Act 2017 permits a registered person — the principal — to send inputs or capital goods, without payment of tax, to a job worker for job work and to bring back the inputs or capital goods after completion. Inputs must be brought back within 1 year of the dispatch date; capital goods must be brought back within 3 years. Alternatively, the principal may supply the goods directly from the job-worker’s premises to a customer within India on payment of tax, or with or without payment of tax for export, subject to the principal declaring the job-worker’s premises as its own additional place of business or the job-worker being registered under GST. Failure to return or further supply within the statutory window triggers a deemed supply on the original dispatch date; the principal becomes liable to pay tax on that deemed supply along with interest under Section 50 accrued from the dispatch date. Interest at 18 percent per annum from the dispatch date compounds rapidly. The reconciliation discipline is a challan-aging report keyed to every open dispatch, with a mid-window alert at 10 months for inputs (return transit time beyond the 12-month mark is not statutorily protected) and a hard-stop exception at 11 months requiring either physical return, a legitimate destination change, or a proactive Section 143 tax payment.

Rule 45 of the CGST Rules 2017 prescribes the operational mechanics. Inputs, semi-finished goods, or capital goods sent to a job worker must move under a challan issued by the principal containing the particulars specified in Rule 55 — a serial number, date, name and address and GSTIN of the principal and consignee, HSN classification, description, quantity, taxable value, tax rate applicable in the event of tax being payable (marked nil where the movement is under Section 143), and place of supply. The details of all challans dispatched to and received from job workers during the reporting period must be included in FORM ITC-04 for that period. Rule 45(4) provides for challan endorsement on further dispatch from one job worker to another and on return; the challan chain from original dispatch to eventual return must be traceable end-to-end.

FORM ITC-04 is the periodic summary return (half-yearly for taxpayers with aggregate turnover up to Rs 5 crore, annual for taxpayers with turnover above Rs 5 crore, per the current CBIC-notified periodicity under Notification 35/2021-CT and successors) that captures the challan-level movement in four categories: goods sent to a job worker, goods received back from a job worker, goods sent from one job worker to another, and goods supplied directly from the job-worker’s place. The return summarises the challan-level detail into aggregate dispatch and return counts and taxable-value totals per category, and any challan still open at the end of the reporting period carries forward into the next period with an aging tag. Filing ITC-04 late or with mismatched aggregates flags a Section 143 exposure at audit and pre-positions the brand-owner for a Section 73 or 74 notice.

HSN 9988 — Manufacturing services on physical inputs owned by others — is the service classification for job work under GST. Sub-heading 998817 or 998818 covers pharmaceutical manufacturing job work depending on the specific formulation and process description. The GST rate on job-work services rendered to a registered person was reduced from 18 percent to 12 percent by Notification 20/2019-CT (Rate) dated 30 September 2019 with effect from 1 October 2019; job work rendered to an unregistered person continues to attract 18 percent. Where the brand-owner (the registered principal) is invoiced for finished-dosage-form conversion by the loan-licensee (also registered), the invoice carries 12 percent GST — split into IGST 12 percent where the parties are in different states, or CGST 6 percent plus SGST 6 percent aggregating to 12 percent where they are in the same state. The API vs formulation HSN 2941/3003/3004 reconciliation guide unpacks the classification of the underlying active pharmaceutical ingredient and finished dosage form separately; the HSN 9988 rate here applies specifically to the job-work service invoice, not to the active pharmaceutical ingredient or the finished goods themselves.

Section 43B(h) of the Income-tax Act 1961 (retained in the Income-tax Act 2025 codification) — inserted by the Finance Act 2023 with effect from assessment year 2024-25 — disallows any sum payable to a Micro or Small enterprise if the payment is not made within the timeline specified in Section 15 of the MSMED Act 2006. Section 15 MSMED sets that timeline at 45 days from the date of acceptance where a written agreement exists between buyer and supplier, and 15 days where no written agreement exists. For a brand-owner running loan-licensing, the third-party manufacturer is often a mid-sized pharma job-work specialist Udyam-registered as Micro or Small — the loan-licensee’s finance profile and installed capacity tend to sit in the Small enterprise band. The brand-owner’s job-work invoice payable is therefore exposed to Section 43B(h): a payment delayed beyond the Section 15 MSMED window disallows the corresponding expense in the year of accrual and defers the deduction to the year of actual payment. The tracking discipline is a payment aging report keyed to each Udyam-flagged loan-licensee, with a mid-window alert at day 30 or day 10 and a year-end reconciliation that classifies every unpaid invoice at the balance-sheet date as either within-window (deductible in the current year) or beyond-window (disallowed and deductible only when paid). The Tax Audit Report Form 3CD Clause 22 disclosure on interest disallowance under MSMED Act Section 16 and Clause 26 disclosure on Section 43B disallowance both draw from this workbook.

The reconciliation failure-mode analysis framework treats the Section 143 challan window as a class-1 control point and the Section 43B(h) aging as a class-2 control point in the loan-licensee reconciliation surface; the monthly-close reconciliation playbook sequences the challan-return match and the job-work invoice ITC utilisation into the standard close cadence.

A worked example — a Tier-1 brand-owner’s Sikkim-to-Baddi loan-licensee cycle

Illustrative — the following figures represent the operating pattern of a Tier-1 Indian pharma brand-owner running a Sikkim manufacturing unit for active pharmaceutical ingredient and intermediate production against a Baddi loan-licensee for finished-dosage-form conversion. Public disclosures do not reveal per-batch dispatch detail; cross-verify against your own challan register or ITC-04 draft before action.

The brand-owner’s Sikkim manufacturing unit (registered under the state’s Section 80-IE eligible manufacturing regime) produces an active pharmaceutical ingredient — a Chapter 2941 antibiotic active — at a monthly volume of 4,200 kilograms across 84 production batches. The Sikkim unit dispatches the entire batch output to a Baddi loan-licensee for compression into finished tablets under the brand-owner’s own brand name. A representative single dispatch: 50 kilograms of active pharmaceutical ingredient in a single batch, taxable value (transfer-price basis for the internal inventory movement) of Rs 68 lakh, HSN 2941, dispatched on 15 September 2026 against Rule 45 challan number CH-SK-2026-09-001 without payment of tax under Section 143. The Baddi loan-licensee receives the material on 17 September 2026, converts the batch into 480,000 tablet units under the brand-owner’s drug licence in accordance with the master batch record and manufacturing specifications supplied by the brand-owner, packs the finished tablets into strip packs, and returns the finished dosage form to the brand-owner’s warehouse in Guwahati on 6 October 2026 against return challan number CH-BD-2026-10-004 referencing the original CH-SK-2026-09-001. The Section 143 1-year clock started on 15 September 2026 — the original dispatch date — and would expire on 14 September 2027 if the finished dosage form were not returned by that date.

The Baddi loan-licensee raises a monthly job-work invoice on 31 October 2026 aggregating the batch-level job-work rates for all batches converted in the month of October. The invoice for this specific batch reports: batch reference RC-2026-10-004 (loan-licensee’s internal reconciliation code), quantity 480,000 tablet units, tariff at Rs 0.85 per tablet under the loan-licensing agreement’s Schedule A, job-work value Rs 4,08,000, HSN 9988 sub-heading 998817. Because the loan-licensee is in Himachal Pradesh (state code 02) and the brand-owner’s registered plant of dispatch is in Sikkim (state code 11), the invoice carries IGST at 12 percent — Rs 48,960 — under Section 8 of the IGST Act. The invoice total is Rs 4,56,960.

The brand-owner’s electronic credit ledger receives the Rs 48,960 IGST credit under the IGST head after the invoice appears in GSTR-2B for October (matched to the loan-licensee’s own GSTR-1 filing). The credit utilises against the brand-owner’s own finished-product output tax under the Section 49(5) utilisation order — IGST credit first against IGST liability, then CGST, then SGST — as the finished tablets are dispatched from Guwahati to distributors and stockists. The reconciliation surface for the brand-owner’s monthly GST close is a three-way match: the internal dispatch challan register (CH-SK-2026-09-001) showing the original active-pharmaceutical-ingredient movement to Baddi; the return challan register (CH-BD-2026-10-004) showing the finished-dosage-form return within the Section 143 window; and the loan-licensee’s HSN 9988 job-work invoice line for batch RC-2026-10-004 matched to the original dispatch challan through the internal batch number and the master batch record cross-reference.

Aggregating across the full quarter — 84 batches per month across 3 months, aggregate active-pharmaceutical-ingredient dispatch value of Rs 172 crore across 252 batches, aggregate job-work value at Rs 0.85 per tablet on 121 million tablets converted of approximately Rs 10.3 crore, aggregate IGST on the job-work invoicing of Rs 1.24 crore — the brand-owner’s ITC-04 draft for the reporting period reports:

The 6 open challans at the end of the period carry forward with a challan-aging tag. If any of those 6 approach the 12-month window in the next reporting cycle, the brand-owner must plan for the finished-dosage-form return or execute a Section 143 payment-of-tax proactively before the deemed-supply crystallises.

Separately, the Section 43B(h) aging tracker classifies the 31 October 2026 monthly job-work invoice — invoice total Rs 4,56,960 for the one batch reference above, and aggregate approximately Rs 3.5 crore for the full month across all batches converted at that loan-licensee — against the 45-day Section 15 MSMED window. The loan-licensee is Udyam-registered as a Small enterprise; the written loan-licensing agreement exists, so the 45-day window applies. Invoice date 31 October 2026 sets the payment deadline at 15 December 2026. If the brand-owner clears the invoice within that window, the entire Rs 3.5 crore is deductible in FY 2026-27; if the balance remains unpaid at 31 March 2027, the unpaid portion is disallowed under Section 43B(h) and deductible only in FY 2027-28 in the year of actual payment.

Finally, the Sikkim unit’s Section 80-IE claim is worked out on the eligible profit derived from the manufacture of the active pharmaceutical ingredient and intermediates at the Sikkim plant — not on the brand-owner’s aggregate profit including the third-party’s finished-dosage-form conversion margin. The transfer-price at which the Sikkim unit values its own active-pharmaceutical-ingredient dispatch to the Baddi loan-licensee (and to any other loan-licensee, or to the brand-owner’s own downstream formulation plant elsewhere) sets the top-line for the Sikkim unit’s 80-IE eligible profit calculation, and the Section 92BA specified-domestic-transaction Rule 10D transfer-pricing documentation must support that price. The Rule 89(5) inverted-duty refund mechanic for pharma formulations does not typically overlap with the loan-licensing cycle at the brand-owner’s own GSTIN — the inversion arises on the finished-formulation sale to distributors after the 22 September 2025 rate transition, not on the job-work invoice — but where the brand-owner runs finished formulations at 5 percent output against 18 percent packaging inputs, the same refund apparatus that runs for the dairy inverted-duty refund cycle under Rule 89(5) applies with Chapter 30 substitution.

Common reconciliation breakages

Five breakages recur across Indian pharma brand-owners running loan-licensing and third-party manufacturing arrangements, and each maps to a specific control failure.

• Section 143 1-year window missed on individual dispatches. The 1-year clock runs from the original dispatch date, not from the loan-licensee’s receipt date or from any subsequent challan re-endorsement. Brand-owners that track window aging against the wrong reference date — receipt at loan-licensee, first sub-batch dispatch, or a re-issued challan — quietly drift into deemed-supply exposure on the older cohort of open dispatches. The Section 50 interest at 18 percent per annum accrues from the actual dispatch date; a 15-month-old open dispatch attracts a full quarter of additional interest beyond the deemed-supply date, which finance teams typically underestimate in the exposure quantification.

• Return challan not keyed to original dispatch challan. Rule 45 requires the challan chain from original dispatch to eventual return to be traceable end-to-end. Loan-licensees that raise return challans referencing their own internal batch codes rather than the original brand-owner dispatch challan number break the chain. The brand-owner’s ITC-04 return then reports return-from-job-worker aggregates that cannot be matched line-by-line to the dispatch aggregates, and the mismatch surfaces at Section 65 GST audit as a broken challan chain that pre-positions a Section 73 or 74 notice on the unmatched portion.

• HSN 9988 job-work invoice rate mis-classification. The 12 percent rate for job work rendered to a registered principal is the effective rate under Notification 20/2019 with effect from 1 October 2019. Loan-licensees that continue to invoice at 18 percent (the pre-October-2019 default that still lingers in some vendor masters) over-collect GST from the brand-owner and expose the brand-owner to a Section 15 GSTR-2B mismatch. Whether the brand-owner claims 18 percent ITC that the loan-licensee did not report at 18 percent, or claims 12 percent ITC on an invoice showing 18 percent, the mismatch triggers a GSTR-2B ITC reconciliation exception at the electronic credit ledger reconciliation.

• Section 43B(h) MSME classification stale. The Micro / Small / Medium classification under the MSMED Act 2006 (as amended) is determined by the Udyam Registration Certificate at the vendor’s end, and the classification can change year-over-year as the vendor’s turnover and investment cross the classification thresholds. A loan-licensee classified as Small at onboarding may re-classify as Medium two years later, in which case the Section 43B(h) 45-day disallowance ceases to apply from the date of re-classification. Conversely, a loan-licensee onboarded as Medium may re-classify down into Small on a subsequent Udyam refresh, and the Section 43B(h) window then applies from that date. The loan-licensee master demands the same vendor-master staleness discipline that the GSTR-2B reconciliation surface applies to GSTIN-cancellation and category-change events on the input side.

• Section 80-IE eligible profit contamination. Brand-owners running a Section 80-IE Sikkim unit sometimes include the third-party’s finished-dosage-form conversion margin in the Sikkim unit’s eligible profit, on the reasoning that the finished dosage form is manufactured under the Sikkim brand-owner’s drug licence. Section 80-IE relief is confined to profits derived from the eligible manufacturing activity carried on at the eligible unit itself — the active-pharmaceutical-ingredient and intermediate manufacture at the Sikkim plant — and does not extend to conversion margins earned by the brand-owner on third-party manufactured finished goods returned to the brand-owner’s account. The contamination inflates the deduction claim and pre-positions a Section 143(3) reassessment on the excess deduction.

How a reconciliation platform handles this

A purpose-built pharma loan-licensing reconciliation platform ingests every Rule 45 challan from the brand-owner’s dispatch plants, every return challan from the loan-licensee network, every HSN 9988 job-work invoice on GSTR-2B, and the Udyam registration status of every loan-licensee — and produces a per-batch chain view that closes the loop from active-pharmaceutical-ingredient dispatch to finished-dosage-form return within the Section 143 window. The platform ages every open dispatch against the 1-year input window and the 3-year capital-goods window with mid-window alerts, matches each loan-licensee HSN 9988 invoice line to the specific dispatch batch through the internal batch number and master batch record cross-reference, reconciles the IGST-versus-CGST-plus-SGST tax head on the job-work invoice against the state combination of the two GSTINs, aggregates the challan-level dispatch and return into the ITC-04 periodic filing base under the four ITC-04 categories, and runs the Section 43B(h) 45-day / 15-day MSME payment aging against every Udyam-flagged loan-licensee invoice with a year-end classification into within-window and beyond-window buckets for the tax provisioning workbook. Match rate improvement of 51 to 88 percent on the challan-to-return-to-invoice chain, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling on the sensitive drug-licence and batch-record data flowing through the loan-licensing network, is what makes the platform an infrastructure investment for a Tier-1 or Tier-2 brand-owner running a network of 25 to 60 loan-licensees rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The Section 143 discipline in this article sets up the foundational reconciliation surface for every Indian pharma brand-owner running loan-licensing or third-party manufacturing. For the classification split between the active pharmaceutical ingredient dispatched under Chapter 2941 or Chapter 30 and the finished dosage form returned under Chapter 30, read the API vs formulation HSN 2941/3003/3004 reconciliation guide. For the 22 September 2025 rate transition that moved all drugs to 5 percent output GST and medical devices from 18 percent to 5 percent, read the 56th GST Council pharma transition walkthrough — the resulting inversion deepens the Rule 89(5) refund cycle for downstream finished formulations. For the Rule 89(5) inverted-duty refund mechanic itself, the dairy inverted-duty refund under Rule 89(5) is the anchor cross-cluster explanation of the amended formula, and the pharma Rule 89(5) walkthrough applies the same mechanic to Chapter 30 formulations. For the methodology framework that treats the Section 143 challan-aging as a class-1 control point, read the reconciliation failure-mode analysis framework; the monthly-close reconciliation playbook sequences the loan-licensee close activities into the standard close cadence. The commercial pillar for the entire pharma cluster is pharma reconciliation software India; the broader authority is reconciliation software India and the GST-specific pillar is GST reconciliation software.

The five FAQs below address the operational questions Indian pharma brand-owner finance controllers and tax leads ask most often when implementing structured Section 143 loan-licensee reconciliation across a multi-state operating network.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 13 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024